The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Scope of the Report:
This report focuses on the Drugs for Vulvovaginal Candidiasis in North America and Europe market, especially in United States, United Kingdom, Canada, Germany, France, Italy and Spain. This report categorizes the market based on manufacturers, countries/Regions, type and application.
Market Segment by Manufacturers, this report covers
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Market Segment by Countries, covering
United States
United Kingdom
Canada
Germany
France
Italy
Spain
Market Segment by Type, covers
Miconazole
Clotrimazole
Fluconazole
Econazole
Other
Market Segment by Applications, can be divided into
Hospital & Clinic
Pharmacy
There are 19 Chapters to deeply display the North America and Europe Drugs for Vulvovaginal Candidiasis market.
Chapter 1, to describe Drugs for Vulvovaginal Candidiasis Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force;
Chapter 2, to analyze the manufacturers of Drugs for Vulvovaginal Candidiasis, with profile, main business, news, sales, price, revenue and market share in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the North America and Europe market by countries, covering United States, United Kingdom, Canada, France, Germany, Italy and Spain, with sales, price, revenue and market share of Drugs for Vulvovaginal Candidiasis, for each country, from 2013 to 2018;
Chapter 5 and 6, to show the market by type and application, with sales, price, revenue, market share and growth rate by type, application, from 2013 to 2018;
Chapter 7, 8, 9, 10, 11, 12 and 13 to analyze the key countries by manufacturers, Type and Application, covering 7 countries, with sales, revenue and market share by manufacturers, types and applications;
Chapter 14, Drugs for Vulvovaginal Candidiasis market forecast, by countries, type and application, with sales, price, revenue and growth rate forecast, from 2018 to 2023;
Chapter 15, to analyze the manufacturing cost, key raw materials and manufacturing process, etc.
Chapter 16, to analyze the industrial chain, sourcing strategy and downstream end users (buyers);
Chapter 17, to describe sales channel, distributors, traders, dealers, etc.
Chapter 18 and 19, to describe the research findings and conclusion, appendix, methodology and data source.
Frequently Asked Questions
These dominant industry players use well planned strategies to occupied highest market share in this market. Some of the top players in [Keyword] business includes.
[Company list]
As per [Keyword] market analysis, North America is forecasted to occupied major share in the [Keyword] market.
The statistical data of the dominant industry player of [Keyword] market can be acquired from the company profile segment described in the report. This segment come up with analysis of major player’s in the [Keyword] market, also their last five-year revenue, segmental, product offerings, key strategies adopted and geographical revenue produced.
The report come up with a segment of the [Keyword] market based on Type, Region, and Application, Also offer a determined view on the [Keyword] market.
The report offers a nitty-gritty estimation of the market by providing data on various viewpoints that incorporate, restraints, drivers, and opportunities threats. This data can help in making suitable decisions for stakeholders before investing.
The sample report for [Keyword] market can be received after the apply from the website.
Table Of Content
Table of Contents
1 Market Overview
1.1 Drugs for Vulvovaginal Candidiasis Introduction
1.2 Market Analysis by Type
1.2.1 Miconazole
1.2.2 Clotrimazole
1.2.3 Fluconazole
1.2.4 Econazole
1.2.5 Other
1.3 Market Analysis by Applications
1.3.1 Hospital & Clinic
1.3.2 Pharmacy
1.4 Market Analysis by Countries
1.4.1 United States Status and Prospect (2013-2023)
1.4.2 Canada Status and Prospect (2013-2023)
1.4.3 United Kingdom Status and Prospect (2013-2023)
1.4.4 Germany Status and Prospect (2013-2023)
1.4.5 France Status and Prospect (2013-2023)
1.4.6 Italy Status and Prospect (2013-2023)
1.4.7 Spain Status and Prospect (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Business Overview
2.1.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Perrigo
2.2.1 Business Overview
2.2.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 J & J
2.3.1 Business Overview
2.3.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pfizer
2.4.1 Business Overview
2.4.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bristol-Myers Squibb
2.5.1 Business Overview
2.5.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Effik
2.6.1 Business Overview
2.6.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.6.2.1 Type 1
2.6.2.2 Type 2
2.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Teva
2.7.1 Business Overview
2.7.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.7.2.1 Type 1
2.7.2.2 Type 2
2.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Sanofi
2.8.1 Business Overview
2.8.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.8.2.1 Type 1
2.8.2.2 Type 2
2.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Cisen Pharmaceutical
2.9.1 Business Overview
2.9.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.9.2.1 Type 1
2.9.2.2 Type 2
2.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Kingyork Group
2.10.1 Business Overview
2.10.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.10.2.1 Type 1
2.10.2.2 Type 2
2.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 North America and Europe Drugs for Vulvovaginal Candidiasis Market Competition, by Manufacturer
3.1 North America and Europe Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
3.2 North America and Europe Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
3.2.1 North America and Europe Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
3.2.2 North America and Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer (2016-2017)
3.3 North America and Europe Drugs for Vulvovaginal Candidiasis Price by Manufacturers (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share (2016-2017)
3.4.2 Top 5 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share (2016-2017)
3.5 Market Competition Trend
4 North America and Europe Drugs for Vulvovaginal Candidiasis Market Analysis by Countries/Regions
4.1 North America and Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries/Regions
4.2 North America and Europe Drugs for Vulvovaginal Candidiasis Sales by Countries/Regions (2013-2018)
4.2.1 North America and Europe Drugs for Vulvovaginal Candidiasis Sales by Countries/Regions (2013-2018)
4.2.2 North America and Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
4.3 North America and Europe Drugs for Vulvovaginal Candidiasis Revenue (Value) by Countries (2013-2018)
4.3.1 North America and Europe Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
4.3.2 North America and Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2013-2018)
5 North America and Europe Market Segmentation Drugs for Vulvovaginal Candidiasis by Type
5.1 North America and Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
5.1.1 North America and Europe Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2013-2018)
5.1.2 North America and Europe Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Type (2013-2018)
5.2 Miconazole Sales Growth and Price
5.2.1 North America and Europe Miconazole Sales Growth (2013-2018)
5.2.2 North America and Europe Miconazole Price (2013-2018)
5.3 Clotrimazole Sales Growth and Price
5.3.1 North America and Europe Clotrimazole Sales Growth (2013-2018)
5.3.2 North America and Europe Clotrimazole Price (2013-2018)
5.4 Fluconazole Sales Growth and Price
5.4.1 North America and Europe Fluconazole Sales Growth (2013-2018)
5.5 Econazole Sales Growth and Price
5.5.1 North America and Europe Econazole Sales Growth (2013-2018)
5.5.2 North America and Europe Econazole Price (2013-2018)
5.6 Other Sales Growth and Price
5.6.1 North America and Europe Other Sales Growth (2013-2018)
5.6.2 North America and Europe Other Price (2013-2018)
6 North America and Europe Market Segmentation Drugs for Vulvovaginal Candidiasis by Application
6.1 North America and Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
6.2 Hospital & Clinic Sales Growth (2013-2018)
6.3 Pharmacy Sales Growth (2013-2018)
7 United States Drugs for Vulvovaginal Candidiasis Sales, Revenue, by Type, Application and Manufacturers
7.1 United States Drugs for Vulvovaginal Candidiasis Revenue, Sales and Growth Rate (2013-2018)
7.2 United States Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2013-2018)
7.2.1 United States Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
7.2.2 United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2013-2018)
7.3 United States Drugs for Vulvovaginal Candidiasis Sales and Market Share by Application (2013-2018)
7.3.1 United States Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
7.3.2 United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
7.4 United States Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Manufacturer (2016-2017)
7.4.1 United States Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
7.4.2 United States Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
7.5 United States Drugs for Vulvovaginal Candidiasis Export and Import (2013-2018)
8 United Kingdom Drugs for Vulvovaginal Candidiasis Sales, Revenue, by Type, Application and Manufacturers
8.1 United Kingdom Drugs for Vulvovaginal Candidiasis Revenue, Sales and Growth Rate (2013-2018)
8.2 United Kingdom Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2016-2017)
8.2.1 United Kingdom Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
8.2.2 United Kingdom Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2013-2018)
8.3 United Kingdom Drugs for Vulvovaginal Candidiasis Sales and Market Share by Application (2013-2018)
8.3.1 United Kingdom Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
8.3.2 United Kingdom Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
8.4 United Kingdom Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Manufacturer (2016-2017)
8.4.1 United Kingdom Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
8.4.2 United Kingdom Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
8.5 United Kingdom Drugs for Vulvovaginal Candidiasis Export and Import (2013-2018)
9 Canada Drugs for Vulvovaginal Candidiasis Sales, Revenue, by Type, Application and Manufacturers
9.1 Canada Drugs for Vulvovaginal Candidiasis Revenue, Sales and Growth Rate (2013-2018)
9.2 Canada Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2013-2018)
9.2.1 Canada Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
9.2.2 Canada Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2013-2018)
9.3 Canada "&Sheet1!$B$1&" Sales and Market Share by Application (2013-2018)"
9.3.1 Canada Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
9.3.2 Canada Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
9.4 Canada Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Manufacturer (2016-2017)
9.4.1 Canada Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
9.4.2 Canada Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
9.5 Canada Drugs for Vulvovaginal Candidiasis Export and Import (2013-2018)
10 Germany Drugs for Vulvovaginal Candidiasis Sales, Revenue, by Type, Application and Manufacturers
10.1 Germany Drugs for Vulvovaginal Candidiasis Revenue, Sales and Growth Rate (2013-2018)
10.2 Germany Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2013-2018)
10.2.1 Germany Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
10.2.2 Germany Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2013-2018)
10.3 Germany Drugs for Vulvovaginal Candidiasis Sales and Market Share by Application (2013-2018)
10.3.1 Germany Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
10.3.2 Germany Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
10.4 Germany Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Manufacturer (2016-2017)
10.4.1 Germany Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
10.4.2 Germany Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
10.5 Germany Drugs for Vulvovaginal Candidiasis Export and Import (2013-2018)
11 France Drugs for Vulvovaginal Candidiasis Sales, Revenue, by Type, Application and Manufacturers
11.1 France Drugs for Vulvovaginal Candidiasis Revenue, Sales and Growth Rate (2013-2018)
11.2 France Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2013-2018)
11.2.1 France Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
11.2.2 France Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2013-2018)
11.3 France "&Sheet1!$B$1&" Sales by Application (2013-2018)"
11.3.1 France Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
11.3.2 France Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
11.4 France Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Manufacturer (2016-2017)
11.4.1 France Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
11.4.2 France Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer
11.5 France Drugs for Vulvovaginal Candidiasis Export and Import (2013-2018)
12 Italy Drugs for Vulvovaginal Candidiasis Sales, Revenue, by Type, Application and Manufacturers
12.1 Italy Drugs for Vulvovaginal Candidiasis Revenue, Sales and Growth Rate (2013-2018)
12.2 Italy Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2013-2018)
12.2.1 Italy Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
12.2.2 Italy Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2013-2018)
12.3 Italy Drugs for Vulvovaginal Candidiasis Sales and Market Share by Application (2013-2018)
12.3.1 Italy Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
12.3.2 Italy Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
12.4 Italy Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Manufacturer (2016-2017)
12.4.1 Italy Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
12.4.2 Italy Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
12.5 Italy Drugs for Vulvovaginal Candidiasis Export and Import (2013-2018)
13 Spain Drugs for Vulvovaginal Candidiasis Sales, Revenue, by Type, Application and Manufacturers
13.1 Spain Drugs for Vulvovaginal Candidiasis Revenue, Sales and Growth Rate (2013-2018)
13.2 Spain Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2013-2018)
13.2.1 Spain Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
13.2.2 Spain Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2013-2018)
13.3 Spain Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
13.3.1 Spain Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
13.3.2 Spain Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
13.4 Spain Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Manufacturer (2016-2017)
13.4.1 Spain Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
13.4.2 Spain Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
13.5 Spain Drugs for Vulvovaginal Candidiasis Export and Import (2013-2018)
14 Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
14.1 North America and Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2018-2023)
14.2 Drugs for Vulvovaginal Candidiasis Market Forecast by Countries/Regions (2018-2023)
14.2.1 United States Drugs for Vulvovaginal Candidiasis Sales and Growth Rate Forecast (2018-2023)
14.2.2 United Kingdom Drugs for Vulvovaginal Candidiasis Sales and Growth Rate Forecast (2018-2023)
14.2.3 Canada Drugs for Vulvovaginal Candidiasis Sales and Growth Rate Forecast (2018-2023)
14.2.4 Germany Drugs for Vulvovaginal Candidiasis Sales and Growth Rate Forecast (2018-2023)
14.2.5 France Drugs for Vulvovaginal Candidiasis Sales and Growth Rate Forecast (2018-2023)
14.2.6 Italy Drugs for Vulvovaginal Candidiasis Sales and Growth Rate Forecast (2018-2023)
14.2.7 Spain Drugs for Vulvovaginal Candidiasis Sales and Growth Rate Forecast (2018-2023)
14.3 Drugs for Vulvovaginal Candidiasis Market Forecast by Type (2018-2023)
14.3.1 North America and Europe Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2018-2023)
14.3.2 North America and Europe Drugs for Vulvovaginal Candidiasis Market Share Forecast by Type (2018-2023)
14.4 Drugs for Vulvovaginal Candidiasis Market Forecast by Application (2018-2023)
14.4.1 North America and Europe Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2018-2023)
14.4.2 North America and Europe Drugs for Vulvovaginal Candidiasis Market Share Forecast by Application (2018-2023)
15 Drugs for Vulvovaginal Candidiasis Manufacturing Cost Analysis
15.1 Drugs for Vulvovaginal Candidiasis Key Raw Materials Analysis
15.1.1 Key Raw Materials
15.1.2 Price Trend of Key Raw Materials
15.1.3 Key Suppliers of Raw Materials
15.1.4 Market Concentration Rate of Raw Materials
15.2 Proportion of Manufacturing Cost Structure
15.2.1 Raw Materials
15.2.2 Labor Cost
15.2.3 Manufacturing Expenses
15.3 Manufacturing Process Analysis of Drugs for Vulvovaginal Candidiasis
16 Industrial Chain, Sourcing Strategy and Downstream Buyers
16.1 Drugs for Vulvovaginal Candidiasis Industrial Chain Analysis
16.2 Upstream Raw Materials Sourcing
16.3 Raw Materials Sources of Drugs for Vulvovaginal Candidiasis Major Manufacturers in 2017
16.4 Downstream Buyers
17 Sales Channel, Distributors, Traders and Dealers
17.1 Sales Channel
17.1.1 Direct Marketing
17.1.2 Indirect Marketing
17.1.3 Marketing Channel Future Trend
17.2 Distributors, Traders and Dealers
18 Research Findings and Conclusion
19 Appendix
19.1 Methodology
19.2 Data Source
Inquiry For Buying
North America and Europe Drugs for Vulvovaginal Candidiasis
Please fill out the form. We will contact you within 24 hours:
All fields required...
Request Sample
North America and Europe Drugs for Vulvovaginal Candidiasis
Please fill out the form. We will contact you within 24 hours:
All fields required...
